Tactile Systems Q2 Revenue Beats, But Guidance Narrowed on Airway Clearance Weakness
TCMD has more than doubled off its 52-week low of $12.01 on elevated volume (2.2× avg).
Summary
Tactile Systems reported Q2 revenue of $85.7M, a 9% increase that slightly beat the $85.5M consensus. Adjusted EBITDA of $11.4M handily exceeded the $8.0M estimate, driven by a 12% jump in lymphedema product sales. However, airway clearance revenue fell 7% as the AffloVest next-gen launch caused temporary inventory disruptions. Management narrowed the full-year revenue outlook to $360M-$366M from $360M-$368M, citing caution on airway clearance, while maintaining EBITDA guidance. The company also repurchased $5.3M in stock during the quarter. The mixed update—strong lymphedema growth offset by airway clearance headwinds and a slight guidance trim—leaves the near-term outlook uncertain.
At the time of this announcement, TCMD was trading at $29.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $657.3M. The 52-week trading range was $12.01 to $37.77. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.